SCID-Xl is a catastrophic disease of childhood caused by mutations in the common gamma chain (YC) leading to defects in cytokine signaling that result in profound deficiencies in both cellular and humoral immunity. Patients that have a matched sibling donor for allogeneic transplant do very well with a greater than 90% long-term disease free survival. However, most patients do not have a matched sibling donor available and typically are treated using a haploidentical, parental transplant. These patients do significantly less well with a long term survival ranging between 60 and 75%. Furthermore, persistent immune defects are present in about 50 to 60 % of the survivors of haploidentical transplants. For these children who lack a matched sibling donor, gene therapy is being developed as an alternate primary therapy and as salvage for allogeneic transplant failures. Prior trials in France, the UK, and in the US have used retroviral vectors developed from the Moloney Leukemia Virus (MLV) in which the y{c} cDNA was driven from the strong viral enhancer/promoter present in the long terminal repeat (LTR). These trials have yielded clear proof of efficacy by showing that the majority of patients had significant immune reconstitution following the gene transfer procedure. However, 5 out of 23 patients have developed T cell leukemia due to transcriptional activation of cellular proto-oncogenes from the strong viral enhancer present in the MLV LTR. We now seek to avoid this complication by using a self-inactivating (SIN) lentiviral vector which contains an internal cellular promoter and chromatin insulator fragments flanking the transcriptional cassette. We have tested this CL20i4-EF1a-hy{c}-OPT vector in preclinical experiments that have confirmed the potential safety and efficacy of this configuration. We have also created a high titer, stable producer cell line for GMP production and have generated a Master Cell Bank in our GMP facility. We now propose two clinical protocols to study the use of this vector in either newly diagnosed patients less than one year old (LVXSCID-ND) or in older children that have failed previous treatment or who present later in life with milder symptoms (LVXSCID-OC). We hypothesize that this lentiviral vector-based approach will provide effective treatment and will be safer than the previous MLV-based vectors. These companion clinical trials should yield a great deal of information about gene therapy for SCID-X1 and more generally about the use of lentiviral vectors for stem cell-targeted, human gene therapy.

Public Health Relevance

This project will test a new method for treating patients with x-linked severe combined immunodeficiency based on using lentiviral vectors and may identify a new treatment option that could be used for the majority of these patients. It is also possible that this study could provide more general information about lentiviral vectors that will lead to new therapies for other types of blood and immune system disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL053749-19
Application #
8531317
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
2015-07-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
19
Fiscal Year
2013
Total Cost
$342,062
Indirect Cost
$137,759
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Yu, Hui; Neale, Geoffrey; Zhang, Hui et al. (2014) Downregulation of Prdm16 mRNA is a specific antileukemic mechanism during HOXB4-mediated HSC expansion in vivo. Blood 124:1737-47
Jackson, Shaun W; Scharping, Nicole E; Kolhatkar, Nikita S et al. (2014) Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol 192:4525-32
Griffith, Linda M; Cowan, Morton J; Notarangelo, Luigi D et al. (2014) Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol 133:335-47
Treanor, Louise M; Zhou, Sheng; Janke, Laura et al. (2014) Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med 211:701-13
De Ravin, Suk See; Gray, John T; Throm, Robert E et al. (2014) False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector. Mol Ther 22:244-5
Nienhuis, Arthur W (2013) Development of gene therapy for blood disorders: an update. Blood 122:1556-64
Zhou, Sheng; Ma, Zhijun; Lu, Taihe et al. (2013) Mouse transplant models for evaluating the oncogenic risk of a self-inactivating XSCID lentiviral vector. PLoS One 8:e62333
Wilber, Andrew; Nienhuis, Arthur W; Persons, Derek A (2011) Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood 117:3945-53
Wilber, Andrew; Hargrove, Phillip W; Kim, Yoon-Sang et al. (2011) Therapeutic levels of fetal hemoglobin in erythroid progeny of ýý-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood 117:2817-26
Kim, Yoon-Sang; Wielgosz, Matthew M; Hargrove, Phillip et al. (2010) Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins. Mol Ther 18:1310-7

Showing the most recent 10 out of 136 publications